Top

Published in:

Open Access 01-12-2007 | Review

Transfusion-transmitted infections

Authors: Florian Bihl, Damiano Castelli, Francesco Marincola, Roger Y Dodd, Christian Brander

Published in: Journal of Translational Medicine | Issue 1/2007

Abstract

Although the risk of transfusion-transmitted infections today is lower than ever, the supply of safe blood products remains subject to contamination with known and yet to be identified human pathogens. Only continuous improvement and implementation of donor selection, sensitive screening tests and effective inactivation procedures can ensure the elimination, or at least reduction, of the risk of acquiring transfusion transmitted infections. In addition, ongoing education and up-to-date information regarding infectious agents that are potentially transmitted via blood components is necessary to promote the reporting of adverse events, an important component of transfusion transmitted disease surveillance. Thus, the collaboration of all parties involved in transfusion medicine, including national haemovigilance systems, is crucial for protecting a secure blood product supply from known and emerging blood-borne pathogens.

Available only for authorised users

Pittman M: A study of bacteria implicated in transfusion reactions and of bacteria isolated from blood products. J Lab Clin Med. 1953, 42 (2): 273-288.PubMed

McEntegart MG: Dangerous contaminants in stored blood. Lancet. 1956, 271 (6949): 909-911. 10.1016/S0140-6736(56)90378-6.PubMed

Snyder EL, Dodd RY: Reducing the risk of blood transfusion. Hematology (Am Soc Hematol Educ Program). 2001, 433-442.

Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herve P: Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002, 42 (10): 1356-1364. 10.1046/j.1537-2995.2002.00202.x.PubMed

Faber JC: Haemovigilance procedure in transfusion medicine. Hematol J. 2004, 5 Suppl 3: S74-82. 10.1038/sj.thj.6200427.PubMed

Faber JC: Worldwide overview of existing haemovigilance systems. Transfus Apher Sci. 2004, 31 (2): 99-110. 10.1016/j.transci.2004.07.004.PubMed

Wagner SJ: Transfusion-transmitted bacterial infection: risks, sources and interventions. Vox Sang. 2004, 86 (3): 157-163. 10.1111/j.0042-9007.2004.00410.x.PubMed

Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL: Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology (Am Soc Hematol Educ Program). 2003, 575-589.

CDC: Fatal Bacterial Infections Associated with Platelet Transfusion-United States, 2004. MMWR Morb Mortal Wkly Rep. 2005, 54 (7): 168-170.

10.

Brecher ME, Hay SN: Bacterial contamination of blood components. Clin Microbiol Rev. 2005, 18 (1): 195-204. 10.1128/CMR.18.1.195-204.2005.PubMedCentralPubMed

11.

Blajchman MA, Goldman M, Baeza F: Improving the bacteriological safety of platelet transfusions. Transfus Med Rev. 2004, 18 (1): 11-24. 10.1016/j.tmrv.2003.10.002.PubMed

12.

American Association of Blood Banks: Guidance on implementation of new bacteria reduction and detection standards . AABB Bulletin. 2004, 04 (07):

13.

Fang CT, Chambers LA, Kennedy J, Strupp A, Fucci MC, Janas JA, Tang Y, Hapip CA, Lawrence TB, Dodd RY: Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion. 2005, 45 (12): 1845-1852. 10.1111/j.1537-2995.2005.00650.x.PubMed

14.

Niu MT, Knippen M, Simmons L, Holness LG: Transfusion-transmitted Klebsiella pneumoniae fatalities, 1995 to 2004. Transfus Med Rev. 2006, 20 (2): 149-157. 10.1016/j.tmrv.2005.11.007.PubMed

15.

Hogman CF, Engstrand L: Serious bacterial complications from blood components--how do they occur?. Transfus Med. 1998, 8 (1): 1-3. 10.1046/j.1365-3148.1998.00118.x.PubMed

16.

Goldman M, Roy G, Frechette N, Decary F, Massicotte L, Delage G: Evaluation of donor skin disinfection methods. Transfusion. 1997, 37 (3): 309-312. 10.1046/j.1537-2995.1997.37397240214.x.PubMed

17.

McDonald CP, Lowe P, Roy A, Robbins S, Hartley S, Harrison JF, Slopecki A, Verlander N, Barbara JA: Evaluation of donor arm disinfection techniques. Vox Sang. 2001, 80 (3): 135-141. 10.1046/j.1423-0410.2001.00029.x.PubMed

18.

Lee CK, Ho PL, Chan NK, Mak A, Hong J, Lin CK: Impact of donor arm skin disinfection on the bacterial contamination rate of platelet concentrates. Vox Sang. 2002, 83 (3): 204-208. 10.1046/j.1423-0410.2002.00219.x.PubMed

19.

Wagner SJ, Robinette D, Friedman LI, Miripol J: Diversion of initial blood flow to prevent whole-blood contamination by skin surface bacteria: an in vitro model. Transfusion. 2000, 40 (3): 335-338. 10.1046/j.1537-2995.2000.40030335.x.PubMed

20.

de Korte D, Marcelis JH, Verhoeven AJ, Soeterboek AM: Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang. 2002, 83 (1): 13-16. 10.1046/j.1423-0410.2002.00189.x.PubMed

21.

Chassaigne M, Vassort-Bruneau C, Allouch P, Audurier A, Boulard G, Grosdhomme F, Noel L, Gulian C, Janus G, Perez P: Reduction of bacterial load by predonation sampling. Transfus Apher Sci. 2001, 24 (3): 253-10.1016/S1473-0502(01)00066-0.PubMed

22.

Brecher ME, Hay SN, Rose AD, Rothenberg SJ: Evaluation of BacT/ALERT plastic culture bottles for use in testing pooled whole blood-derived leukoreduced platelet-rich plasma platelets with a single contaminated unit. Transfusion. 2005, 45 (9): 1512-1517. 10.1111/j.1537-2995.2005.00563.x.PubMed

23.

Brecher ME, Hay SN, Rothenberg SJ: Validation of BacT/ALERT plastic culture bottles for use in testing of whole-blood-derived leukoreduced platelet-rich-plasma-derived platelets. Transfusion. 2004, 44 (8): 1174-1178. 10.1111/j.1537-2995.2004.04033.x.PubMed

24.

McDonald CP, Roy A, Lowe P, Robbins S, Hartley S, Barbara JA: Evaluation of the BacT/Alert automated blood culture system for detecting bacteria and measuring their growth kinetics in leucodepleted and non-leucodepleted platelet concentrates. Vox Sang. 2001, 81 (3): 154-160. 10.1046/j.0042-9007.2001.00104.x.PubMed

25.

Ortolano GA, Freundlich LF, Holme S, Russell RL, Cortus MA, Wilkins K, Nomura H, Chong C, Carmen R, Capetandes A, Wenz B: Detection of bacteria in WBC-reduced PLT concentrates using percent oxygen as a marker for bacteria growth. Transfusion. 2003, 43 (9): 1276-1285. 10.1046/j.1537-2995.2003.00487.x.PubMed

26.

Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med. 2004, 351 (8): 760-768. 10.1056/NEJMoa040085.PubMed

27.

Schuttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S: Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA. Lancet. 2000, 355 (9197): 41-42. 10.1016/S0140-6736(99)04719-4.PubMed

28.

Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S: Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev. 2005, 19 (2): 110-126. 10.1016/j.tmrv.2004.11.005.PubMed

29.

Kleinman S, Chan P, Robillard P: Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003, 17 (2): 120-162.PubMed

30.

Dodd RY, Notari EP, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002, 42 (8): 975-979. 10.1046/j.1537-2995.2002.00174.x.PubMed

31.

Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. Jama. 2003, 289 (8): 959-962. 10.1001/jama.289.8.959.PubMed

32.

Laperche S: Blood safety and nucleic acid testing in Europe. Euro Surveill. 2005, 10 (2): 3-4.PubMed

33.

Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levicnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle L, Niederhauser C, Pastila S, Pillonel J, Pineau J, van der Poel CL, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, Stramer SL, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A: Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang. 2005, 88 (4): 289-303. 10.1111/j.1423-0410.2005.00636_1.x.PubMed

34.

Busch GM: Closing the window on viral transmission by blood transfusion. Blood Savety in the new millenium. Edited by: SL S. 2001, Bethesda, MD , American Asssociation of Blood Banks, 33-54.

35.

Offergeld R, Faensen D, Ritter S, Hamouda O: Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill. 2005, 10 (2): 8-11.PubMed

36.

Niederhauser C, Schneider P, Fopp M, Ruefer A, Levy G: Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003. Euro Surveill. 2005, 10 (2): 14-16.PubMed

37.

Velati C, Fomiatti L, Baruffi L, Romano L, Zanetti A: Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill. 2005, 10 (2): 12-14.PubMed

38.

Soldan K, Davison K, Dow B: Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996 to 2003. Euro Surveill. 2005, 10 (2): 17-19.PubMed

39.

Pillonel J, Laperche S: Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill. 2005, 10 (2): 5-8.PubMed

40.

Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez JM, Oyonarte Gomez S: Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill. 2005, 10 (2): 20-22.PubMed

41.

Delwart E, Kuhns MC, Busch MP: Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: Implications for blood safety, diagnostics, treatment, and molecular epidemiology. J Med Virol. 2006, 78 Suppl 1: S30-5. 10.1002/jmv.20604.PubMed

42.

Yugi H, Hino S, Satake M, Tadodoro K: Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology in Japan. Vox Sang. 2005, 89 (4): 265-10.1111/j.1423-0410.2005.00694.x.PubMed

43.

Brojer E: Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology in Poland. Vox Sang. 2005, 89 (4): 267-268. 10.1111/j.1423-0410.2005.00696.x.PubMed

44.

Weber B: Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005, 32 (2): 102-112. 10.1016/j.jcv.2004.10.008.PubMed

45.

Yoshikawa A, Gotanda Y, Itabashi M, Minegishi K, Kanemitsu K, Nishioka K: HBV NAT positive [corrected] blood donors in the early and late stages of HBV infection: analyses of the window period and kinetics of HBV DNA. Vox Sang. 2005, 88 (2): 77-86. 10.1111/j.1423-0410.2005.00602.x.PubMed

46.

Soldan K, Barbara JA, Ramsay ME, Hall AJ: Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang. 2003, 84 (4): 274-286. 10.1046/j.1423-0410.2003.00296.x.PubMed

47.

Biswas R, Tabor E, Hsia CC, Wright DJ, Laycock ME, Fiebig EW, Peddada L, Smith R, Schreiber GB, Epstein JS, Nemo GJ, Busch MP: Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003, 43 (6): 788-798. 10.1046/j.1537-2995.2003.00424.x.PubMed

48.

Sanchez-Quijano A, Jauregui JI, Leal M, Pineda JA, Castilla A, Abad MA, Civeira MP, Garcia de Pesquera F, Prieto J, Lissen E: Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol. 1993, 17 (3): 288-293. 10.1016/S0168-8278(05)80207-7.PubMed

49.

Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G: Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology. 2000, 31 (2): 507-512. 10.1002/hep.510310235.PubMed

50.

Coleman PF: Detecting hepatitis B surface antigen mutants. Emerg Infect Dis. 2006, 12 (2): 198-203.PubMedCentralPubMed

51.

Weber B: Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol. 2006, 78 Suppl 1: S59-65. 10.1002/jmv.20610.PubMed

52.

Tabor E: Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol. 2006, 78 Suppl 1: S43-7. 10.1002/jmv.20606.PubMed

53.

Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS: Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006, 44 (1): 39-46. 10.1016/j.jhep.2005.06.016.PubMed

54.

Prati D, Gerosa A, Porretti L: Occult HBV infection and blood transfusion. J Hepatol. 2006, 44 (4): 818-10.1016/j.jhep.2005.12.009.PubMed

55.

Jongerius JM, Wester M, Cuypers HT, van Oostendorp WR, Lelie PN, van der Poel CL, van Leeuwen EF: New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays. Transfusion. 1998, 38 (1): 56-59. 10.1046/j.1537-2995.1998.38198141499.x.PubMed

56.

Levicnik-Stezinar S: Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. Clin Lab. 2004, 50 (1-2): 49-51.PubMed

57.

CDC: West Nile Virus, Statistics, Surveillance, and Control. Accessed:4/25/2006, [http://wwwcdcgov/ncidod/dvbid/westnile/indexhtm]

58.

Gould LH, Fikrig E: West Nile virus: a growing concern?. J Clin Invest. 2004, 113 (8): 1102-1107. 10.1172/JCI200421623.PubMedCentralPubMed

59.

Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME: Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003, 349 (13): 1236-1245. 10.1056/NEJMoa030969.PubMed

60.

CDC: Update: Investigations of West Nile virus infections in recipients of organ transplantation and blood transfusion. MMWR Morb Mortal Wkly Rep. 2002, 51 (37): 833-836.

61.

Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH: Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing. N Engl J Med. 2005, 353 (5): 460-467. 10.1056/NEJMoa044029.PubMed

62.

Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY: West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med. 2005, 353 (5): 451-459. 10.1056/NEJMoa044333.PubMed

63.

Petersen LR, Epstein JS: Problem solved? West Nile virus and transfusion safety. N Engl J Med. 2005, 353 (5): 516-517. 10.1056/NEJMe058144.PubMed

64.

Custer B, Busch MP, Marfin AA, Petersen LR: The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med. 2005, 143 (7): 486-492.PubMed

65.

Korves CT, Goldie SJ, Murray MB: Cost-effectiveness of alternative blood-screening strategies for West Nile Virus in the United States. PLoS Med. 2006, 3 (2): e21-10.1371/journal.pmed.0030021.PubMedCentralPubMed

66.

Koppelman MH, Sjerps MS, de Waal M, Reesink HW, Cuypers HT: No evidence of West Nile virus infection in Dutch blood donors. Vox Sang. 2006, 90 (3): 166-169. 10.1111/j.1423-0410.2006.00754.x.PubMed

67.

Manns A, Hisada M, La Grenade L: Human T-lymphotropic virus type I infection. Lancet. 1999, 353 (9168): 1951-1958. 10.1016/S0140-6736(98)09460-4.PubMed

68.

Murphy EL, Glynn SA, Fridey J, Sacher RA, Smith JW, Wright DJ, Newman B, Gibble JW, Ameti DI, Nass CC, Schreiber GB, Nemo GJ: Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis. 1997, 176 (6): 1468-1475.PubMed

69.

Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, Newman B, Ownby HE, Garratty G, Hutching ST, Schreiber GB: Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis. 2004, 10 (1): 109-116.PubMedCentralPubMed

70.

Roucoux DF, Murphy EL: The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev. 2004, 6 (3): 144-154.PubMed

71.

Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005, 24 (39): 6058-6068. 10.1038/sj.onc.1208968.PubMed

72.

Stramer SL, Foster GA, Dodd RY: Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion. 2006, 46 (5): 703-707. 10.1111/j.1537-2995.2006.00788.x.PubMed

73.

Vamvakas EC: Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. Transfus Med Rev. 2005, 19 (3): 181-199. 10.1016/j.tmrv.2005.02.002.PubMed

74.

Blajchman MA: The clinical benefits of the leukoreduction of blood products. J Trauma. 2006, 60 (6 Suppl): S83-90.PubMed

75.

Visconti MR, Pennington J, Garner SF, Allain JP, Williamson LM: Assessment of removal of human cytomegalovirus from blood components by leukocyte depletion filters using real-time quantitative PCR. Blood. 2004, 103 (3): 1137-1139. 10.1182/blood-2003-03-0762.PubMed

76.

Blajchman MA, Goldman M, Freedman JJ, Sher GD: Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev. 2001, 15 (1): 1-20. 10.1053/tmrv.2001.19946.PubMed

77.

Knowles DM, Cesarman E: The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases. Ann Oncol. 1997, 8 Suppl 2: 123-129. 10.1023/A:1008263123314.PubMed

78.

Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, Banage F, Nzaro E, Kataaha P, Dondero TJ, Pellett PE, Lackritz EM: Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006, 355 (13): 1331-1338. 10.1056/NEJMoa055009.PubMed

79.

Dollard SC, Nelson KE, Ness PM, Stambolis V, Kuehnert MJ, Pellett PE, Cannon MJ: Possible transmission of human herpesvirus-8 by blood transfusion in a historical United States cohort. Transfusion. 2005, 45 (4): 500-503. 10.1111/j.0041-1132.2005.04334.x.PubMed

80.

Regamey N, Tamm M, Wernli M, Witschi A, Thiel G, Cathomas G, Erb P: Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients. N Engl J Med. 1998, 339 (19): 1358-1363. 10.1056/NEJM199811053391903.PubMed

81.

Dodd RY: Human herpesvirus-8: what (not) to do?. Transfusion. 2005, 45 (4): 463-465. 10.1111/j.0041-1132.2005.05008.x.PubMed

82.

Blajchman MA, Vamvakas EC: The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006, 355 (13): 1303-1305. 10.1056/NEJMp068178.PubMed

83.

Wu CG, Mason B, Jong J, Erdman D, McKernan L, Oakley M, Soucie M, Evatt B, Yu MY: Parvovirus B19 transmission by a high-purity factor VIII concentrate. Transfusion. 2005, 45 (6): 1003-1010. 10.1111/j.1537-2995.2005.04387.x.PubMed

84.

Koenigbauer UF, Eastlund T, Day JW: Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion. 2000, 40 (10): 1203-1206. 10.1046/j.1537-2995.2000.40101203.x.PubMed

85.

Plentz A, Hahn J, Knoll A, Holler E, Jilg W, Modrow S: Exposure of hematologic patients to parvovirus B19 as a contaminant of blood cell preparations and blood products. Transfusion. 2005, 45 (11): 1811-1815. 10.1111/j.1537-2995.2005.00610.x.PubMed

86.

Blumel J, Schmidt I, Effenberger W, Seitz H, Willkommen H, Brackmann HH, Lower J, Eis-Hubinger AM: Parvovirus B19 transmission by heat-treated clotting factor concentrates. Transfusion. 2002, 42 (11): 1473-1481. 10.1046/j.1537-2995.2002.00221.x.PubMed

87.

Koppelman MH, Cuypers HT, Emrich T, Zaaijer HL: Quantitative real-time detection of parvovirus B19 DNA in plasma. Transfusion. 2004, 44 (1): 97-103. 10.1046/j.0041-1132.2004.00610.x.PubMed

88.

Gowland P, Fontana S, Niederhauser C, Taleghani BM: Molecular and serologic tracing of a transfusion-transmitted hepatitis A virus. Transfusion. 2004, 44 (11): 1555-1561. 10.1111/j.1537-2995.2004.04071.x.PubMed

89.

Diwan AH, Stubbs JR, Carnahan GE: Transmission of hepatitis A via WBC-reduced RBCs and FFP from a single donation. Transfusion. 2003, 43 (4): 536-540. 10.1046/j.1537-2995.2003.00342.x.PubMed

90.

Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo CG: Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfus Med. 2006, 16 (2): 79-83. 10.1111/j.1365-3148.2006.00652.x.PubMed

91.

Matsubayashi K, Nagaoka Y, Sakata H, Sato S, Fukai K, Kato T, Takahashi K, Mishiro S, Imai M, Takeda N, Ikeda H: Transfusion-transmitted hepatitis E caused by apparently indigenous hepatitis E virus strain in Hokkaido, Japan. Transfusion. 2004, 44 (6): 934-940. 10.1111/j.1537-2995.2004.03300.x.PubMed

92.

Nishizawa T, Okamoto H, Konishi K, Yoshizawa H, Miyakawa Y, Mayumi M: A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun. 1997, 241 (1): 92-97. 10.1006/bbrc.1997.7765.PubMed

93.

Tanaka Y, Primi D, Wang RY, Umemura T, Yeo AE, Mizokami M, Alter HJ, Shih JW: Genomic and molecular evolutionary analysis of a newly identified infectious agent (SEN virus) and its relationship to the TT virus family. J Infect Dis. 2001, 183 (3): 359-367. 10.1086/318091.PubMed

94.

Hitzler WE, Runkel S: Prevalence, persistence and liver enzyme levels of HGV RNA-positive blood donors determined by large-scale screening and transmission by blood components. Clin Lab. 2004, 50 (1-2): 25-31.PubMed

95.

Zhong S, Yeo W, Lin CK, Lin XR, Tang MW, Johnson PJ: Quantitative and genotypic analysis of TT virus infection in Chinese blood donors. Transfusion. 2001, 41 (8): 1001-1007. 10.1046/j.1537-2995.2001.41081001.x.PubMed

96.

Jeon MJ, Shin JH, Suh SP, Lim YC, Ryang DW: TT virus and hepatitis G virus infections in Korean blood donors and patients with chronic liver disease. World J Gastroenterol. 2003, 9 (4): 741-744.PubMed

97.

Akiba J, Umemura T, Alter HJ, Kojiro M, Tabor E: SEN virus: epidemiology and characteristics of a transfusion-transmitted virus. Transfusion. 2005, 45 (7): 1084-1088. 10.1111/j.1537-2995.2004.00209.x.PubMed

98.

Kumar D, Humar A: Emerging viral infections in transplant recipients. Curr Opin Infect Dis. 2005, 18 (4): 337-341. 10.1097/01.qco.0000172697.44784.ff.PubMed

99.

Kitchen AD, Chiodini PL: Malaria and blood transfusion. Vox Sang. 2006, 90 (2): 77-84. 10.1111/j.1423-0410.2006.00733.x.PubMed

100.

World Health Organization: Malaria. Fact Sheet No 94. [http://www.who.int/mediacentre/factsheets/fs094/en/]

101.

Kinde G, Oke J, Gnahoui I, Massougbodji A: [The risk of malaria transmission by blood transfusion at Cotonou, Benin]. Sante. 2000, 10 (6): 389-392.

102.

Frey-Wettstein M, Maier A, Markwalder K, Munch U: A case of transfusion transmitted malaria in Switzerland. Swiss Med Wkly. 2001, 131 (21-22): 320-PubMed

103.

Purdy E, Perry E, Gorlin J, Jensen K: Transfusion-transmitted malaria: unpreventable by current donor exclusion guidelines?. Transfusion. 2004, 44 (3): 464-10.1111/j.1537-2995.2003.00352.x.PubMed

104.

Alkassab F, Ericsson CD: Transfusion-transmitted malaria: how satisfactory are current preventative measures?. Am J Med. 2006, 119 (5): e1-2. 10.1016/j.amjmed.2005.11.008.PubMed

105.

Reesink HW: European strategies against the parasite transfusion risk. Transfus Clin Biol. 2005, 12 (1): 1-4. 10.1016/j.tracli.2004.12.001.PubMed

106.

Mungai M, Tegtmeier G, Chamberland M, Parise M: Transfusion-transmitted malaria in the United States from 1963 through 1999. N Engl J Med. 2001, 344 (26): 1973-1978. 10.1056/NEJM200106283442603.PubMed

107.

Seed CR, Kitchen A, Davis TM: The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria. Transfus Med Rev. 2005, 19 (3): 229-240. 10.1016/j.tmrv.2005.02.004.PubMed

108.

American Association of Blood Banks: Standards for Blood Banks and Transfusion Services. Edited by: Banks AAB. 2002, Bethesda, MD, 21st

109.

Kitchen A, Mijovic A, Hewitt P: Transfusion-transmitted malaria: current donor selection guidelines are not sufficient. Vox Sang. 2005, 88 (3): 200-201. 10.1111/j.1423-0410.2005.00610.x.PubMed

110.

Chiodini PL, Hartley S, Hewitt PE, Barbara JA, Lalloo K, Bligh J, Voller A: Evaluation of a malaria antibody ELISA and its value in reducing potential wastage of red cell donations from blood donors exposed to malaria, with a note on a case of transfusion-transmitted malaria. Vox Sang. 1997, 73 (3): 143-148. 10.1046/j.1423-0410.1997.7330143.x.PubMed

111.

Silvie O, Thellier M, Rosenheim M, Datry A, Lavigne P, Danis M, Mazier D: Potential value of Plasmodium falciparum-associated antigen and antibody detection for screening of blood donors to prevent transfusion-transmitted malaria. Transfusion. 2002, 42 (3): 357-362. 10.1046/j.1537-2995.2002.00050.x.PubMed

112.

Leiby DA, Herron RM, Read EJ, Lenes BA, Stumpf RJ: Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion. 2002, 42 (5): 549-555. 10.1046/j.1537-2995.2002.00077.x.PubMed

113.

Leiby DA: Threats to blood safety posed by emerging protozoan pathogens. Vox Sang. 2004, 87 Suppl 2: 120-122. 10.1111/j.1741-6892.2004.00467.x.PubMed

114.

Schmunis GA, Cruz JR: Safety of the blood supply in Latin America. Clin Microbiol Rev. 2005, 18 (1): 12-29. 10.1128/CMR.18.1.12-29.2005.PubMedCentralPubMed

115.

Cardo LJ: Leishmania: risk to the blood supply. Transfusion. 2006, 46 (9): 1641-1645. 10.1111/j.1537-2995.2006.00941.x.PubMed

116.

Saito-Ito A, Tsuji M, Wei Q, He S, Matsui T, Kohsaki M, Arai S, Kamiyama T, Hioki K, Ishihara C: Transfusion-acquired, autochthonous human babesiosis in Japan: isolation of Babesia microti-like parasites with hu-RBC-SCID mice. J Clin Microbiol. 2000, 38 (12): 4511-4516.PubMedCentralPubMed

117.

Leiby DA: Babesiosis and blood transfusion: flying under the radar. Vox Sang. 2006, 90 (3): 157-165. 10.1111/j.1423-0410.2006.00740.x.PubMed

118.

Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F: Transmission of prion diseases by blood transfusion. J Gen Virol. 2002, 83 (Pt 11): 2897-2905.PubMed

119.

Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG: Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004, 363 (9407): 417-421. 10.1016/S0140-6736(04)15486-X.PubMed

120.

Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW: Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet. 2004, 364 (9433): 527-529. 10.1016/S0140-6736(04)16811-6.PubMed

121.

Health Protection Agency: New case of transfusion-associated variant-CJD. CDR weekly. 2006, 16 (6):

122.

Hewitt PE, Llewelyn CA, Mackenzie J, Will RG: Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang. 2006, 91 (3): 221-230. 10.1111/j.1423-0410.2006.00833.x.PubMed

123.

Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM: Estimation of the number of people incubating variant CJD. Lancet. 1998, 352 (9137): 1353-1354. 10.1016/S0140-6736(05)60744-1.PubMed

124.

Aznar JA, Molina R, Montoro JM: Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion. 1999, 39 (7): 748-750. 10.1046/j.1537-2995.1999.39070748.x.PubMed

125.

Hellstern P: Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol. 2004, 11 (5): 346-350. 10.1097/01.moh.0000137915.88478.23.PubMed

126.

Pelletier JP, Transue S, Snyder EL: Pathogen inactivation techniques. Best Pract Res Clin Haematol. 2006, 19 (1): 205-242. 10.1016/j.beha.2005.04.001.PubMed

127.

Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59. BioDrugs. 2003, 17 (1): 66-68. 10.2165/00063030-200317010-00006.

128.

Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, Porter S, Lin L, Metzel P, Conlan MG: Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion. 2006, 46 (4): 562-571. 10.1111/j.1537-2995.2006.00761.x.PubMed

129.

Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, Lin JS, Corash L, Conlan MG: Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion. 2006, 46 (1): 24-33. 10.1111/j.1537-2995.2005.00671.x.PubMed

130.

Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Hogman CF: Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000, 78 (4): 209-216. 10.1159/000031183.PubMed

131.

Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K: Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV. Antimicrob Agents Chemother. 2003, 47 (2): 475-479. 10.1128/AAC.47.2.475-479.2003.PubMedCentralPubMed

132.

McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood. 2004, 104 (5): 1534-1541. 10.1182/blood-2003-12-4443.PubMed

133.

Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, Wages D, Lin JS, Wood L, Corash L, Conlan MG: Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion. 2005, 45 (11): 1739-1749. 10.1111/j.1537-2995.2005.00583.x.PubMed

134.

Zavizion B, Pereira M, de Melo Jorge M, Serebryanik D, Mather TN, Chapman J, Miller NJ, Alford B, Bzik DJ, Purmal A: Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry. Transfusion. 2004, 44 (5): 731-738. 10.1111/j.1537-2995.2004.03207.x.PubMed

135.

Zavizion B, Serebryanik D, Chapman J, Alford B, Purmal A: Inactivation of Gram-negative and Gram-positive bacteria in red cell concentrates using INACTINE PEN110 chemistry. Vox Sang. 2004, 87 (3): 143-149. 10.1111/j.1423-0410.2004.00556.x.PubMed

136.

Mather T, Takeda T, Tassello J, Ohagen A, Serebryanik D, Kramer E, Brown F, Tesh R, Alford B, Chapman J, Lazo A: West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion. 2003, 43 (8): 1029-1037. 10.1046/j.1537-2995.2003.00464.x.PubMed

137.

Ohagen A, Gibaja V, Horrigan J, Lunderville D, Jayarama V, Marcello J, Chapman J, Lazo A: Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110. Vox Sang. 2004, 87 (1): 1-9. 10.1111/j.1423-0410.2004.00532.x.PubMed

138.

Corbin F: Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer. Int J Hematol. 2002, 76 Suppl 2: 253-257.PubMed

139.

Goodrich RP: The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang. 2000, 78 Suppl 2: 211-215.PubMed

140.

Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns Adu P: Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang. 2006, 90 (4): 279-285. 10.1111/j.1423-0410.2006.00761.x.PubMed

141.

Fast LD, Dileone G, Li J, Goodrich R: Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006, 46 (4): 642-648. 10.1111/j.1537-2995.2006.00777.x.PubMed

142.

Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R: Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light. Vox Sang. 2006, 90 (2): 85-91. 10.1111/j.1423-0410.2005.00736.x.PubMed

143.

Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP: Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004, 44 (6): 877-885. 10.1111/j.1537-2995.2004.03355.x.PubMed

144.

Engelfriet CP, Reesink HW, Brand B, Levy G, Williamson LM, Menitove JE, Heier HE, Jorgensen J, Politis C, Seyfried H, Smit Sibinga CT, Faber JC, Vesga MA, Selivanov E, Danilova T, Tadokoro K, Krusius T, Hafner V, Snopek I, Reali G, d'Almeida Goncalves J: Haemovigilance systems. Vox Sang. 1999, 77 (2): 110-120. 10.1046/j.1423-0410.1999.77201101.x.PubMed

145.

Debeir J, Noel L, Aullen J, Frette C, Sari F, Mai MP, Cosson A: The French haemovigilance system. Vox Sang. 1999, 77 (2): 77-81. 10.1159/000031080.PubMed

Title: Transfusion-transmitted infections
Authors: Florian Bihl
Damiano Castelli
Francesco Marincola
Roger Y Dodd
Christian Brander
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2007
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-5-25

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects

"In vitro" and multicolor phenotypic characterization of cell subpopulations identified in fresh human adipose tissue stromal vascular fraction and in the derived mesenchymal stem cells

Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8+ T lymphocytes

Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma

N-myristoyltransferase: A potential novel diagnostic marker for colon cancer

Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials